Rhumbline Advisers Buys 2,988 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

Rhumbline Advisers boosted its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 7.7% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 41,896 shares of the company’s stock after acquiring an additional 2,988 shares during the quarter. Rhumbline Advisers owned approximately 0.15% of Castle Biosciences worth $912,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in Castle Biosciences by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 1,494,176 shares of the company’s stock valued at $33,096,000 after purchasing an additional 32,695 shares during the period. Bellevue Group AG lifted its position in Castle Biosciences by 0.4% during the 4th quarter. Bellevue Group AG now owns 1,232,378 shares of the company’s stock valued at $26,595,000 after purchasing an additional 4,347 shares during the period. Parkman Healthcare Partners LLC lifted its position in Castle Biosciences by 59.0% during the 4th quarter. Parkman Healthcare Partners LLC now owns 357,156 shares of the company’s stock valued at $7,707,000 after purchasing an additional 132,564 shares during the period. Intrinsic Edge Capital Management LLC lifted its position in Castle Biosciences by 108.8% during the 4th quarter. Intrinsic Edge Capital Management LLC now owns 326,270 shares of the company’s stock valued at $7,041,000 after purchasing an additional 170,000 shares during the period. Finally, Acadian Asset Management LLC lifted its position in Castle Biosciences by 130.7% during the 1st quarter. Acadian Asset Management LLC now owns 210,824 shares of the company’s stock valued at $4,669,000 after purchasing an additional 119,443 shares during the period. Institutional investors own 92.60% of the company’s stock.

Insider Buying and Selling at Castle Biosciences

In other Castle Biosciences news, Director Daniel Bradbury sold 7,883 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $26.65, for a total transaction of $210,081.95. Following the completion of the sale, the director now owns 8,550 shares of the company’s stock, valued at approximately $227,857.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Daniel Bradbury sold 7,883 shares of Castle Biosciences stock in a transaction on Monday, August 12th. The stock was sold at an average price of $26.65, for a total transaction of $210,081.95. Following the completion of the sale, the director now owns 8,550 shares of the company’s stock, valued at $227,857.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Kristen M. Oelschlager sold 2,793 shares of the business’s stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $22.06, for a total value of $61,613.58. Following the completion of the transaction, the chief operating officer now directly owns 145,825 shares of the company’s stock, valued at approximately $3,216,899.50. The disclosure for this sale can be found here. Insiders sold 33,665 shares of company stock valued at $828,222 in the last quarter. 7.20% of the stock is currently owned by insiders.

Castle Biosciences Price Performance

Shares of CSTL opened at $29.97 on Tuesday. The stock has a market capitalization of $827.38 million, a P/E ratio of -26.06 and a beta of 1.02. Castle Biosciences, Inc. has a twelve month low of $12.07 and a twelve month high of $32.53. The company has a 50 day moving average of $26.52 and a 200-day moving average of $23.34. The company has a quick ratio of 7.92, a current ratio of 8.12 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last released its earnings results on Monday, August 5th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.47. Castle Biosciences had a negative net margin of 1.08% and a negative return on equity of 0.77%. The business had revenue of $87.00 million during the quarter, compared to analysts’ expectations of $69.95 million. During the same period last year, the business earned ($0.70) earnings per share. As a group, equities research analysts forecast that Castle Biosciences, Inc. will post -0.58 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on CSTL shares. Robert W. Baird upped their target price on shares of Castle Biosciences from $34.00 to $37.00 and gave the company an “outperform” rating in a research report on Tuesday, August 6th. Stephens reissued an “overweight” rating and set a $37.00 target price on shares of Castle Biosciences in a research note on Tuesday, August 6th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Castle Biosciences currently has an average rating of “Buy” and a consensus target price of $32.80.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.